扶化瘀胶囊联合抗病毒治疗延缓慢性乙肝患者肝纤维化病变的随访研究

A following up study on postponing hepatic fibrosis in patients with chronic hepatitis B with the Fuzheng Huayu capsule plus antiviral therapy

目的:研究扶正化瘀胶囊联合抗病毒治疗延缓慢性乙肝患者肝纤维化病变的效果。方法:选取我院2014年6月-2015年7月82例慢性乙肝肝纤维化患者为研究对象,采用随机数表法将患者分组为观察组和对照组,每组41例。对照组采用抗病毒治疗,观察组在对照组的基础上服用扶正化瘀胶囊。比较两组治疗前后肝功能、肝纤维化指标及彩色B超指标。结果:观察组治疗后谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBi L)分别为(52.36±21.36)、(39.12±18.56)、(17.65±8.93),观察组低于对照组及治疗前,两组比较差异有统计学意义(P<0.05)。观察组治疗后透明质酸(HA)、层粘蛋白(LN)、Ⅳ型胶原(IV-C)分别为(107.85±81.36)、(125.36±73.65)、(90.56±65.23),低于对照组及治疗前,两组比较,差异有统计学意义(P<0.05)。观察组治疗后脾脏长度、脾脏厚度分别为(8.51±0.41)、(2.98±0.12),低于对照组及治疗前,两组比较,差异有统计学意义(P<0.05)。结论:扶正化瘀胶囊联合抗病毒治疗慢性乙肝纤维化优于单纯使用一种药物,可有效恢复肝功能,抑制肝纤维化,值得临床应用和推广。

Objective:To study the effect of the Fuzheng Huayu capsule with antiviral therapy on fibrosis in patients with chronic hepatitis B.Methods:82patients were randomly divided into the control group(41cases)and observation group(41cases).Both groups were treated by antiviral therapy;the observation group was given the Fuzheng Huayu capsule more.Results:After treatment,the alanine aminotransferase,aspartate aminotransferase,total bilirubin,hyaluronic acid,laminin,collagen type IV,length and thickness of spleen inthe observation group were respectively(52.36±21.36),(39.12±18.56),(17.65±8.93),(107.85±81.36),(125.36±73.65),(90.56±65.23),(8.51±0.41)and(2.98±0.12),were lower than those in the control group and before treatment(P<0.05).Conclusion:The Fuzheng Huayu capsule with antiviral therapy was more effective on fibrosis in patients with chronic hepatitis B,can not only effectively restore liver function,but also inhibit hepatic fibrosis,and is worthy of clinical application and promotion.